Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article

World Journal of Gastroenterology

Volumn 22, Issue 34, 2016, Pages 7727-7734

  Chao, Che Yung ^a   Battat, Robert ^a   Al Khoury, Alex ^a   Restellini, Sophie ^b   Sebastiani, Giada ^a   Bessissow, Talat ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Crohn's disease; Metabolic syndrome; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Ulcerative colitis

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ALPHA TOCOPHEROL; AZATHIOPRINE; FARNESOID X RECEPTOR AGONIST; GLUCOCORTICOID; INFLIXIMAB; LIVER PROTECTIVE AGENT; MERCAPTOPURINE; METHOTREXATE; OBETICHOLIC ACID; PENTOXIFYLLINE; PIOGLITAZONE; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; STEROID; TUMOR NECROSIS FACTOR;

ASSESSMENT OF HUMANS; BODY MASS; CARBOHYDRATE METABOLISM; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EXPOSURE; DRUG USE; DYSBIOSIS; ECHOGRAPHY; ENVIRONMENTAL FACTOR; HEPATIC STEATOSIS INDEX; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INSULIN RESISTANCE; INTESTINE MUCOSA PERMEABILITY; LIFESTYLE MODIFICATION; LIPID METABOLISM; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PARENTERAL NUTRITION; PATHOGENESIS; PREVALENCE; REVIEW; RISK ASSESSMENT; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; STEROID THERAPY; TRANSIENT ELASTOGRAPHY; ANTAGONISTS AND INHIBITORS; COMPLICATION; INFLAMMATORY BOWEL DISEASES; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; RISK FACTOR;

HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INSULIN RESISTANCE; NON-ALCOHOLIC FATTY LIVER DISEASE; PARENTERAL NUTRITION; PREVALENCE; PROGNOSIS; RISK FACTORS; STEROIDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84988654483     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i34.7727     Document Type: Review

References (52)

1. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-384 [PMID: 20494470 DOI: 10.1016/j.jhep.2010.04.008]
2. Beaton MD. Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Can J Gastroenterol 2012; 26: 353-357 [PMID: 22720278 DOI: 10.1155/2012/725468]
3. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419 [PMID: 10348825 DOI: 10.1016/S0016-5085(99)70506-8]
4. Ahmed A, Wong RJ, Harrison SA. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. Clin Gastroenterol Hepatol 2015; 13: 2062-2070 [PMID: 26226097 DOI: 10.1016/j.cgh.2015.07.029]
5. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009; 49: 1017-1044 [PMID: 19243014 DOI: 10.1002/hep.22742]
6. Rocchi A, Benchimol EI, Bernstein CN, Bitton A, Feagan B, Panaccione R, Glasgow KW, Fernandes A, Ghosh S. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol 2012; 26: 811-817 [PMID: 23166905 DOI: 10.1155/2012/984575]
7. Kappelman MD, Rifas-Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand RJ, Finkelstein JA. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5: 1424-1429 [PMID: 17904915 DOI: 10.1016/j.cgh.2007.07.012]
8. Cappello M, Randazzo C, Bravatà I, Licata A, Peralta S, Craxì A, Almasio PL. Liver Function Test Abnormalities in Patients with Inflammatory Bowel Diseases: A Hospital-based Survey. Clin Med Insights Gastroenterol 2014; 7: 25-31 [PMID: 24966712 DOI: 10.4137/CGast.S13125]
9. Román AL, Muñoz F. Comorbidity in inflammatory bowel disease. World J Gastroenterol 2011; 17: 2723-2733 [PMID: 21734780 DOI: 10.3748/wjg.v17.i22.2723]
10. Bringiotti R, Ierardi E, Lovero R, Losurdo G, Di Leo A, Principi M. Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? World J Gastrointest Pathophysiol 2014; 5: 550-559 [PMID: 25400998 DOI: 10.4291/wjgp.v5.i4.550]
11. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascianà R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP, Grieco A. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887 [PMID: 19291785 DOI: 10.1002/hep.22848]
12. Gisbert JP, Luna M, González-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, Maté J. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis 2007; 13: 1106-1114 [PMID: 17455203 DOI: 10.1002/ibd.20160]
13. Sourianarayanane A, Garg G, Smith TH, Butt MI, McCullough AJ, Shen B. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis 2013; 7: e279-e285 [PMID: 23158500 DOI: 10.1016/j.crohns.2012.10.015]
14. Bargiggia S, Maconi G, Elli M, Molteni P, Ardizzone S, Parente F, Todaro I, Greco S, Manzionna G, Bianchi Porro G. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol 2003; 36: 417-420 [PMID: 12702985]
15. Barbero-Villares A, Mendoza Jiménez-Ridruejo J, Taxonera C, López-Sanromán A, Pajares R, Bermejo F, Pérez-Calle JL, Mendoza JL, Algaba A, Moreno-Otero R, Maté J, Gisbert JP. Evaluation of liver fibrosis by transient elastography (Fibroscan) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. Scand J Gastroenterol 2012; 47: 575-579 [PMID: 22229701 DOI: 10.3109/00365521.2011.647412]
16. Thin LW, Lawrance IC, Spilsbury K, Kava J, Olynyk JK. Detection of liver injury in IBD using transient elastography. J Crohns Colitis 2014; 8: 671-677 [PMID: 24529605 DOI: 10.1016/j.crohns.2013.12.006]
17. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082-1090 [PMID: 21618575 DOI: 10.1002/hep.24452]
18. de Fazio C, Torgano G, de Franchis R, Meucci G, Arrigoni M, Vecchi M. Detection of liver involvement in inflammatory bowel disease by abdominal ultrasound scan. Int J Clin Lab Res 1992; 21: 314-317 [PMID: 1591385]
19. Riegler G, D'Incà R, Sturniolo GC, Corrao G, Del Vecchio Blanco C, Di Leo V, Carratù R, Ingrosso M, Pelli MA, Morini S, Valpiani D, Cantarini D, Usai P, Papi C, Caprilli R. Hepatobiliary alterations in patients with inflammatory bowel disease: a multicenter study. Caprilli & amp; Gruppo Italiano Studio Colon-Retto. Scand J Gastroenterol 1998; 33: 93-98 [PMID: 9489915]
20. Verma S, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int 2013; 33: 1398-1405 [PMID: 23763360 DOI: 10.1111/liv.12226]
21. Yamamoto-Furusho JK, Sánchez-Osorio M, Uribe M. Prevalence and factors associated with the presence of abnormal function liver tests in patients with ulcerative colitis. Ann Hepatol 2010; 9: 397-401 [PMID: 21057158]
22. Bessissow T, Le NH, Rollet K, Afif W, Bitton A, Sebastiani G. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016; 22: 1937-1944 [PMID: 27379445 DOI: 10.1097/MIB.0000000000000832]
23. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther 2012; 36: 815-823 [PMID: 22966992 DOI: 10.1111/apt.12046]
24. Liu TC, Stappenbeck TS. Genetics and Pathogenesis of Inflammatory Bowel Disease. Annu Rev Pathol 2016; 11: 127-148 [PMID: 26907531 DOI: 10.1146/annurev-pathol-012615-044152]
25. Nagahori M, Hyun SB, Totsuka T, Okamoto R, Kuwahara E, Takebayashi T, Naganuma M, Watanabe M. Prevalence of metabolic syndrome is comparable between inflammatory bowel disease patients and the general population. J Gastroenterol 2010; 45: 1008-1013 [PMID: 20414788 DOI: 10.1007/s00535-010-0247-z]
26. Yorulmaz E, Adali G, Yorulmaz H, Ulasoglu C, Tasan G, Tuncer I. Metabolic syndrome frequency in inflammatory bowel diseases. Saudi J Gastroenterol 2011; 17: 376-382 [PMID: 22064334 DOI: 10.4103/1319-3767.87177]
27. Fukuda K, Fujita Y. Determination of the discriminant score of intestinal microbiota as a biomarker of disease activity in patients with ulcerative colitis. BMC Gastroenterol 2014; 14: 49 [PMID: 24641276 DOI: 10.1186/1471-230X-14-49]
28. Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: So far, so near. World J Hepatol 2015; 7: 315-326 [PMID: 25848461 DOI: 10.4254/wjh.v7.i3.315]
29. Allard JP. Other disease associations with non-alcoholic fatty liver disease (NAFLD). Best Pract Res Clin Gastroenterol 2002; 16: 783-795 [PMID: 12406445 DOI: 10.1053/bega.2002.0330]
30. Dolinsky VW, Douglas DN, Lehner R, Vance DE. Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone. Biochem J 2004; 378: 967-974 [PMID: 14662008]
31. D'souza AM, Beaudry JL, Szigiato AA, Trumble SJ, Snook LA, Bonen A, Giacca A, Riddell MC. Consumption of a high-fat diet rapidly exacerbates the development of fatty liver disease that occurs with chronically elevated glucocorticoids. Am J Physiol Gastrointest Liver Physiol 2012; 302: G850-G863 [PMID: 22268100 DOI: 10.1152/ajpgi.00378.2011]
32. Rockall AG, Sohaib SA, Evans D, Kaltsas G, Isidori AM, Monson JP, Besser GM, Grossman AB, Reznek RH. Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography. Eur J Endocrinol 2003; 149: 543-548 [PMID: 14640995]
33. Hubel JM, Schmidt SA, Mason RA, Haenle MM, Oeztuerk S, Koenig W, Boehm BO, Kratzer W, Graeter T, Flechtner-Mors M. Influence of plasma cortisol and other laboratory parameters on nonalcoholic Fatty liver disease. Horm Metab Res 2015; 47: 479-484 [PMID: 25295415 DOI: 10.1055/s-0034-1389982]
34. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, Danese S, D'Hoore A, Gassull M, Gomollón F, Hommes DW, Michetti P, O'Morain C, Oresland T, Windsor A, Stange EF, Travis SP. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010; 4: 28-62 [PMID: 21122489 DOI: 10.1016/j.crohns.2009.12.002]
35. Bath RK, Brar NK, Forouhar FA, Wu GY. A review of methotrexate-associated hepatotoxicity. J Dig Dis 2014; 15: 517-524 [PMID: 25139707 DOI: 10.1111/1751-2980.12184]
36. Sakthiswary R, Chan GY, Koh ET, Leong KP, Thong BY. Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis. ScientificWorldJournal 2014; 2014: 823763 [PMID: 24971392 DOI: 10.1155/2014/823763]
37. Hardwick RN, Clarke JD, Lake AD, Canet MJ, Anumol T, Street SM, Merrell MD, Goedken MJ, Snyder SA, Cherrington NJ. Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis. Toxicol Sci 2014; 142: 45-55 [PMID: 25080921 DOI: 10.1093/toxsci/kfu156]
38. Ruiz AG, Casafont F, Crespo J, Cayón A, Mayorga M, Estebanez A, Fernadez-Escalante JC, Pons-Romero F. Lipopolysaccharidebinding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 2007; 17: 1374-1380 [PMID: 18000721 DOI: 10.1007/s11695-007-9243-7]
39. Bahcecioglu IH, Yalniz M, Ataseven H, Ilhan N, Ozercan IH, Seckin D, Sahin K. Levels of serum hyaluronic acid, TNFalpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology 2005; 52: 1549-1553 [PMID: 16201116]
40. Barbuio R, Milanski M, Bertolo MB, Saad MJ, Velloso LA. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol 2007; 194: 539-550 [PMID: 17761893 DOI: 10.1677/JOE-07-0234]
41. Koca SS, Bahcecioglu IH, Poyrazoglu OK, Ozercan IH, Sahin K, Ustundag B. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine-and choline-deficient diet. Inflammation 2008; 31: 91-98 [PMID: 18066656 DOI: 10.1007/s10753-007-9053-z]
42. Yalcin M, Akarsu M, Celik A, Sagol O, Tunali S, Ertener O, Bengi G, Akpinar H. A comparison of the effects of infliximab, adalimumab, and pentoxifylline on rats with non-alcoholic steatohepatitis. Turk J Gastroenterol 2014; 25 Suppl 1: 167-175 [PMID: 25910299 DOI: 10.5152/tjg.2014.5121]
43. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 2365-2368 [PMID: 15571584 DOI: 10.1111/j.1572-0241.2004.40064.x]
44. Gisbert JP, González-Lama Y, Maté J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007; 102: 1518-1527 [PMID: 17391318]
45. Angelico M, Della Guardia P. Review article: hepatobiliary complications associated with total parenteral nutrition. Aliment Pharmacol Ther 2000; 14 Suppl 2: 54-57 [PMID: 10903005 DOI: 10.1046/j.1365-2036.2000.014s2054.x]
46. Howard L, Ashley C. Management of complications in patients receiving home parenteral nutrition. Gastroenterology 2003; 124: 1651-1661 [PMID: 12761723 DOI: 10.1016/S0016-5085(03)00326-3]
47. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-1609 [PMID: 22656328 DOI: 10.1053/j.gastro.2012.04.001]
48. European Association for the Study of the Liver (EASL). Electronic address: easloffice@easloffice.eu; European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402 [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.004]
49. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121-129 [PMID: 19827166 DOI: 10.1002/hep.23276]
50. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685 [PMID: 20427778 DOI: 10.1056/NEJMoa0907929]
51. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebocontrolled trial. Lancet 2015; 385: 956-965 [PMID: 25468160 DOI: 10.1016/S0140-6736(14)61933-4]
52. Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, Raverdy V, Leteurtre E, Dharancy S, Louvet A, Romon M, Duhamel A, Pattou F, Mathurin P. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. Gastroenterology 2015; 149: 379-388; quiz e15-e16 [PMID: 25917783 DOI: 10.1053/j.gastro.2015.04.014]